Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2006

View Archived Issues

Q2 review at Schering-Plough

Phase III study of MyVax in follicular NHL recommended to continue

Exclusivity period expires for business combination of BCY LifeSciences with Pipex

NicAlert to be used in new smoking cessation study

NAP treatment beneficial in model of neonatal encephalopathy

Caspase inhibition with z-VAD-FMK attenuates immediate islet mass loss in transplanted mice

Annamycin and WP-744 selectively induce apoptosis of donor T cells allowing transplant tolerance

Cardioprotective effects of a new amphiphilic spin-trap derived from PBN

Protectan CBLB-502 demonstrates effectiveness in ARS in primates

Phyton Biotech to develop Iplex manufacturing process

New Novavax vaccine to protect against H5N1 clade 2 influenza virus

AMDL compiles FDA requested data for DR-70 cancer test

sBLA filed for CAIV-T in young children

Receptor BioLogix acquires cancer vaccine Insegia

Phase III PolyHeme study completes enrollment

European orphan drug status recommended for BiovaxID in follicular lymphoma

Pozen to submit full response to Trexima approvable letter in Q4

Phase I study findings for IV DNA + protein vaccine DP6-001

Tavocept fails to meet endpoints in phase III neuropathy trials

Schering hit by insufficient results for sargramostim and Ultravist recall

Temodal approved in Japan for malignant glioma

Remicade approved in Europe as monotherapy for psoriatic arthritis

Chantix now available in U.S.

Novel therapeutic agents for HIV infection reported by Tibotec, Pfizer

Novel agents for HCV and gastric emptying cited in recent patents

European approval for NovoRapid in pregnant women with diabetes

Bristol-Myers Squibb patents novel coagulation Factor VIIa inhibitors

Vernalis reports on novel PDEIII/IV inhibitors with bronchodilator and antiinflammatory activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...